Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Core Insights - Entera Bio Ltd. announced new in vivo pharmacokinetic and pharmacodynamic data supporting the development of a long-acting parathyroid hormone (PTH) analog for hypoparathyroidism, which could lead to a once-daily oral tablet treatment [1][4] Group 1: Product Development - The proprietary PTH analog achieved sustained calcium elevation for over three days from a single oral tablet, contrasting with unmodified PTH(1-34) controls that showed no calcium response [1][8] - Entera's previous Phase 2 study demonstrated a 42% reduction in median calcium supplement use while maintaining serum calcium levels above the lower limit for hypoparathyroidism patients [3] - The current preclinical data represent a significant advancement towards a single, once-daily tablet, addressing the dosing burden of existing treatments [3][5] Group 2: Market Context - Hypoparathyroidism is a rare endocrine disorder characterized by deficient PTH production, leading to hypocalcemia and hyperphosphatemia, with current treatments requiring daily or weekly injections [2] - The only approved PTH replacement treatment requires daily injections, highlighting the need for more convenient alternatives [2] Group 3: Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab platform [7] - The company is also developing other oral peptide programs targeting conditions such as osteoporosis and obesity, indicating a broad pipeline aimed at significant unmet medical needs [7]